文献速递毛发、甲与色素性疾病

系统综述与间接治疗比较:利特昔替尼对比巴瑞替尼治疗斑秃

Systematic review and indirect treatment comparisons of ritlecitinib against baricitinib in alopecia areata.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2024-10-24

本研究通过系统综述与贝叶斯网络荟萃分析,间接比较利特昔替尼50mg与巴瑞替尼4mg治疗重度斑秃的疗效与安全性。纳入4项RCT,第24周SALT≤10和SALT≤20的OR分别为0.96和2.16,可信区间均跨越无效线,提示两者疗效无显著差异,但不确定性较大。

要点

  • 利特昔替尼50mg与巴瑞替尼4mg在第24周SALT≤10和SALT≤20结局上无显著差异。
  • ML-NMR调整协变量后发现效应修饰证据,但相对疗效结论不变。
  • 第48/52周非锚定人群调整间接比较结果与主要分析一致。

核心结论

  • 利特昔替尼50mg与巴瑞替尼4mg治疗重度斑秃的疗效相似。

研究设计与样本

  • 系统综述与贝叶斯网络荟萃分析,纳入4项RCT(ALLEGRO 2a、ALLEGRO 2b/3、BRAVE-AA1、BRAVE-AA2)。
  • 使用利特昔替尼个体患者数据通过多水平网络荟萃回归进行人群调整间接比较。

主要发现

  • 第24周SALT≤10的OR为0.96(95% CrI 0.18-7.21),SALT≤20的OR为2.16(95% CrI 0.48-16.46),均无显著差异。
  • ML-NMR调整性别、基线SALT评分、当前发作持续时间和疾病病程后发现效应修饰证据,但相对疗效不变。
  • 第48/52周非锚定人群调整间接比较结果与主要分析一致。

关键数值与推荐

  • 共同主要终点为第24周SALT≤20和SALT≤10。
  • 非锚定人群调整间接比较评估第48/52周SALT≤10和SALT≤20终点。

临床怎么用

  • 临床决策中利特昔替尼50mg与巴瑞替尼4mg可视为疗效相近的选择。
  • 需结合患者个体特征及安全性偏好进行选择。

局限性

  • 仅纳入4项RCT,不确定性较大。
  • 存在效应修饰证据,提示需进一步高质量研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Ritlecitinib and baricitinib are recently approved systemic treatments for severe alopecia areata (AA). Both demonstrated superiority over placebo in hair regrowth measured by the Severity of Alopecia Tool (SALT), but they have not been directly compared in randomized controlled trials (RCTs). We conducted a systematic review of RCTs evaluating treatments in AA and estimated the efficacy and safety of ritlecitinib and baricitinib at Week 24 using Bayesian network meta-analysis. To adjust and explore effect modifiers, population-adjusted indirect comparison was performed via multilevel network meta-regression (ML-NMR) using ritlecitinib individual patient data (IPD). Co-primary endpoints were SALT ≤20 and SALT ≤10 at Week 24. Unanchored population adjusted ITCs were also computed to evaluate SALT ≤10 and SALT ≤20 endpoints at Week 48/52. Four RCTs (ALLEGRO 2a [NCT02974868], ALLEGRO 2b/3 [NCT03732807], BRAVE-AA1 [NCT03570749] and BRAVE-AA2 [NCT03899259]) were included. No evidence of a difference between ritlecitinib 50 mg and baricitinib 4 mg on SALT ≤10 (odds ratio, OR: 0.96, 95% credible interval, CrI: 0.18-7.21) and SALT ≤20 (OR: 2.16, 95% CrI: 0.48-16.46) at Week 24 was found. ML-NMR using ALLEGRO IPD adjusted for sex, SALT score at baseline, duration of current episode and disease duration found evidence of effect modification, although relative efficacy between ritlecitinib 50 mg and baricitinib 4 mg remained unchanged. Unanchored population-adjusted ITC at Week 48/52 was consistent with previous results. We found similar efficacy between ritlecitinib 50 mg and baricitinib 4 mg. These ITCs was informed by only four RCTs, uncertainty was considerable, and there was evidence of effect modification, highlighting the need for further quality research in AA.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Aceituno D, Fawsitt CG, Power GM, et al. Systematic review and indirect treatment comparisons of ritlecitinib against baricitinib in alopecia areata. J Eur Acad Dermatol Venereol. 2024. PMID: 39445776. doi:10.1111/jdv.20372

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。